Dupont Capital Management’s Regenxbio RGNX Stock Holding History

Dupont Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,135	Closed	-$418K	–	1260
2019 Q2	$418K	Sell	8,135 -9,868	-55%	-$493K	0.01%	860
2019 Q1	$1.03M	Hold	18,003	–	–	0.02%	543
2018 Q4	$755K	Hold	18,003	–	–	0.02%	609
2018 Q3	$1.36M	Hold	18,003	–	–	0.03%	491
2018 Q2	$1.29M	Buy	+18,003	New	+$860K	0.03%	482

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dupont Capital Management's RGNX Position: Q3 2019 in Review

Dupont Capital Management sold out of Regenxbio (RGNX) in Q3 2019, closing a stake of 8,135 shares — an estimated $418K sold.

Dupont Capital Management first reported a position in RGNX in Q2 2018 and held it in 5 quarters. The position peaked at $1.36M in Q3 2018. 168 funds tracked by Wall St. Rank hold RGNX as of Q3 2019.

Dupont Capital Management reported no remaining Regenxbio position as of Q3 2019 after selling out during the quarter.
Dupont Capital Management sold 8,135 Regenxbio shares in Q3 2019, an estimated $418K.
Dupont Capital Management first reported a position in Regenxbio in Q2 2018 and held it in 5 quarters.
Dupont Capital Management's Regenxbio position peaked at $1.36M in Q3 2018.
168 funds tracked by Wall St. Rank held Regenxbio as of Q3 2019.

Based on Dupont Capital Management's 13F filing for Q3 2019, filed 28 Oct 2019.